Camelid-Derived Nanobodies Targeting Human Epidermal Growth Factor Receptor: Screening, Expression, and Functional Validation

Yunfeng Liu, Qiting Huang, Dongna Zhang, Yuyi Wang, Shuaiying Zhao, Jianchuan Wen, Yingying Kong, Jianfeng XuAntibodies 2026 · DOI

TL;DR

This paper introduces two novel camelid-derived nanobodies, Nb2H4 and Nb2B6, that specifically target the human Epidermal Growth Factor Receptor (EGFR). These nanobodies demonstrate high affinity binding, recognize distinct epitopes, and show promising functional activity by inhibiting EGF-induced cell proliferation in EGFR-overexpressing cancer cells.

What Problem Does This Paper Address?

The Epidermal Growth Factor Receptor (EGFR) is a critical protein involved in cell growth and proliferation, and its dysregulation is a hallmark of many cancers. While EGFR is a well-established therapeutic target, existing antibody-based treatments have limitations such as poor tissue penetration and high molecular weight. Nanobodies, derived from camelid heavy-chain antibodies, offer a promising alternative due to their small size, high stability, and strong antigen-binding capabilities. However, there's a need for well-characterized, specific nanobodies that can target EGFR and serve as versatile tools for research and therapeutic development, particularly those that recognize distinct epitopes for potential combination therapies.

Methods

The researchers employed a multi-step approach to generate and characterize their EGFR-targeting nanobodies:

  • Immunization and Library Construction: Bactrian camels were immunized with whole cells engineered to overexpress human EGFR. Peripheral blood lymphocytes were then used to construct a high-diversity phage display nanobody library.
  • Biopanning: The library underwent two rounds of biopanning against immobilized EGFR to enrich for specific binders.
  • Screening and Selection: Individual clones were screened using ELISA to identify those that specifically bound to EGFR.
  • Recombinant Expression and Purification: Promising nanobody candidates were expressed in E. coli and purified using nickel-affinity chromatography and size-exclusion chromatography.
  • Binding Characterization:
    • SEC-HPLC: Used to assess complex formation between nanobodies and EGFR, and to evaluate potential epitope competition.
  • Bio-layer Interferometry (BLI) using Octet system: Employed to determine binding kinetics (association and dissociation rates) and affinities (KD values) of the nanobodies to EGFR.
  • Flow Cytometry: Utilized to confirm nanobody binding to endogenously expressed EGFR on cancer cell lines (5637) and to assess specificity against EGFR-low cells (HEK-293T).
  • Functional Validation: A CCK-8 assay was performed to evaluate the effect of the nanobodies on EGF-induced cell proliferation in EGFR-overexpressing cells.

Datasets

Not discussed in the paper. The study generated its own experimental data through the described methods.

Key Insights and Ideas

  • Successful Generation of Dual-Epitope Nanobodies: The study successfully identified two nanobodies (Nb2H4 and Nb2B6) that bind to distinct, non-competing epitopes on the EGFR extracellular domain. This is significant because it opens avenues for developing bispecific nanobodies or combination therapies that could offer enhanced efficacy.
  • High Affinity and Specificity: Both nanobodies demonstrated high binding affinities (sub-nanomolar to picomolar range for Nb2H4, and low nanomolar for Nb2B6) and excellent specificity for EGFR, even on native cell surfaces.
  • Functional Inhibition of Proliferation: Nb2H4 showed a clear ability to suppress EGF-induced cell proliferation in a concentration-dependent manner, highlighting its potential as a therapeutic agent.
  • Nanobodies as Versatile Tools: The work underscores the utility of nanobodies as modular tools for various applications, including epitope mapping, structural studies, and the development of novel antibody engineering strategies.

Key Results

  • Identification of Two Nanobodies: Nb2H4 and Nb2B6 were successfully isolated and characterized.
  • Distinct Epitope Recognition: SEC-HPLC analysis indicated that Nb2H4 and Nb2B6 bind to different regions on EGFR, as evidenced by the formation of ternary complexes without competitive binding.
  • High Binding Affinities:
    • Nb2B6: KD of approximately 1.93 nM.
  • Nb2H4: Apparent high-affinity interaction in the sub-nanomolar to picomolar range.
  • Specific Cell Surface Binding: Flow cytometry confirmed that Nb2H4 and Nb2B6 effectively recognized EGFR on EGFR-high 5637 cells (17.56% and 24.04% positive, respectively) while showing minimal binding to EGFR-low 293T cells (<2% positive).
  • Inhibition of Cell Proliferation: Nb2H4 significantly reduced EGF-induced cell proliferation in EGFR-overexpressing cells, with statistically significant differences observed at concentrations of 60 nM and above.

Limitations and Future Work

  • In Vitro Model: The functional validation was performed using an in vitro cell model (HEK-293T cells overexpressing EGFR). The authors suggest that further investigation in more physiologically relevant experimental systems is warranted.
  • Further Investigation: The identified nanobodies are proposed as molecular tools for epitope mapping, structural studies, and further exploration of EGFR-directed antibody engineering strategies, implying that these are logical next steps.
  • In Vivo Efficacy: While promising, the current study focuses on in vitro characterization. Future work would likely involve assessing the in vivo efficacy and pharmacokinetics of these nanobodies in animal models of cancer.

Summary updated

Abstract

Objectives: The epidermal growth factor receptor (EGFR) is a clinically relevant membrane receptor that is frequently overexpressed or dysregulated in multiple types of cancer, making it an important target for antibody-based strategies. Nanobodies, derived from camelid heavy-chain antibodies, possess favorable properties such as small size, high stability, and strong antigen-binding capacity. This study aimed to generate EGFR-specific nanobodies and to systematically characterize their binding properties and initial functional activity. Methodology: Bactrian camels were immunized with a whole-cell antigen prepared from 293F cells transiently transfected to express full-length human EGFR. A high-diversity phage display nanobody library was constructed from peripheral blood lymphocytes. After two rounds of biopanning against EGFR, positive clones were screened and selected. The identified nanobodies were recombinantly expressed in Escherichia coli and purified. Binding specificity, epitope relationships, and kinetic parameters were evaluated using high-performance liquid chromatography (HPLC), bio-layer interferometry (Octet), and flow cytometry. The effect of selected nanobodies on EGF-induced cell proliferation was evaluated using a CCK-8 assay. Results: Two EGFR-specific nanobodies, Nb2H4 and Nb2B6, were successfully isolated. Both nanobodies exhibited specific binding to EGFR and recognized distinct, non-competing epitopes. Kinetic analyses revealed favorable binding affinities, and flow cytometry confirmed their ability to recognize EGFR in its native cellular context. In addition, Nb2H4 significantly suppressed EGF-induced proliferation in an EGFR-overexpression cell model, indicating preliminary functional activity. Conclusions: This study reports on the successful generation and in vitro characterization of EGFR-targeting nanobodies based on the extracellular domain of EGFR. The identified nanobodies provide useful molecular tools for epitope mapping, structural studies, and the further exploration of EGFR-directed antibody engineering strategies.
BibTeX
@inproceedings{liu2026camelid,
  author = {Yunfeng Liu and Qiting Huang and Dongna Zhang and Yuyi Wang and Shuaiying Zhao and Jianchuan Wen and Yingying Kong and Jianfeng Xu},
  title = {{Camelid-Derived Nanobodies Targeting Human Epidermal Growth Factor Receptor: Screening, Expression, and Functional Validation}},
  booktitle = {Antibodies},
  year = {2026},
  doi = {10.3390/antib15020019},
}
Figure